Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
D000208:Acute Disease; D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab